545
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Analgesic Treatment Approach for Postherpetic Neuralgia: A Narrative Review

, M.DORCID Icon, , M.DORCID Icon, , M.DORCID Icon & , M.DORCID Icon
Pages 184-193 | Received 14 May 2021, Accepted 23 Jan 2023, Published online: 02 Feb 2023

References

  • Johnson RW, Rice ASC. Postherpetic Neuralgia [Internet]. doi:10.1056/NEJMcp1403062. Massachusetts Medical Society; 2014. [cited 2021 Mar 7]. Available from: https://www.nejm.org/doi/10.1056/NEJMcp1403062.
  • Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447–454.
  • Ngo AL, Urits I, Yilmaz M, Fortier L, Anya A, Oh JH, et al. Postherpetic neuralgia: current evidence on the topical film-forming spray with bupivacaine hydrochloride and a review of available treatment strategies. Adv Ther. 2020;37(5):2003–2016.
  • Hadley GR, Gayle JA, Ripoll J, Jones MR, Argoff CE, Kaye RJ, Kaye AD. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016;20(3):17.
  • Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–819. doi:10.1016/S1474-4422(10)70143-5.
  • Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson RW. The impact of Varicella zoster virus: chronic pain. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2010;48(Suppl 1):S8–S13.
  • Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, Langan SM. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30–54.
  • Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92(1–2):139–145.
  • Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, et al. A Comprehensive Algorithm for Management of Neuropathic Pain. Pain Med Off J Am Acad Pain Med. 2019;20(Suppl 1):S2–S12.
  • Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.
  • Ueda Y, Uta D, Tanbo S, Kawabata A, Kanayama S, Osaki M, Nozawa N, Matsumoto T, Andoh T. Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1. J Dermatol Sci. 2020;98(1):50–57.
  • Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2013;3:CD005582. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005582.pub4/full?highligh
  • Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011;3:CD007795.
  • Fan H, Yu W, Zhang Q, Cao H, Li J, Wang J, Shao Y, Hu X. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2014;39(4):334–342.
  • Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
  • Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev [Internet]. 2019;2019(1):CD007076. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353204/.
  • Sumitani M, Sakai T, Matsuda Y, Abe H, Yamaguchi S, Hosokawa T, Fukui S. Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians. J Anesth. 2018;32(3):463–478.
  • Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2017;96(10):656–663.
  • Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial. J Pain. 2005;6(11):741–746.
  • Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–S14. doi:10.4065/mcp.2009.0649.
  • Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13(6):327–331.
  • Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015;14(2):162–173.
  • Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134–142. doi:10.3810/pgm.2011.09.2469.
  • Huang J, Yang S, Yang J, Sun W, Jiang C, Zhou J, Li D, Xiong D, Bates D, Xiao L, et al. Early treatment with temporary spinal cord stimulation effectively prevents development of postherpetic neuralgia. Pain Physician. 2020;23(2):E219–E230.
  • Demant DT, Lund K, Finnerup NB, Vollert J, Maier C, Segerdahl MS, Jensen TS, Sindrup SH. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. Pain. 2015;156(11):2234–2244. doi:10.1097/j.pain.0000000000000266.
  • Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J. Acute pain management: scientific evidence. Med J Aust. 2016;204(8):315–317. doi:10.5694/mja16.00133.
  • Gudin J, Nalamachu S. Utility of lidocaine as a topical analgesic and improvements in patch delivery systems. Postgrad Med. 2020;132(1):28–36. doi:10.1080/00325481.2019.1702296.
  • Baron R, Allegri M, Correa-Illanes G, Hans G, Serpell M, Mick G, Mayoral V. The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther. 2016;5(2):149–169. doi:10.1007/s40122-016-0060-3.
  • Singh S, Gupta R, Kaur S, Kaur J. Post-herpetic neuralgia: a review of current management strategies. Indian J Pain. 2013;27(1):12.
  • Webster LR, Nunez M, Tark MD, Dunteman ED, Lu B, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiol. 2011;11:25. doi:10.1186/1471-2253-11-25.
  • Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21(2 Pt 1):265–270. doi:10.1016/s0190-9622(89)70171-7.
  • Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15(3):510–526.
  • Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;2012(7):CD008943.
  • Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532–543. doi:10.1111/bph.14105.
  • Schutzer-Weissmann J, Farquhar-Smith P. Post-herpetic neuralgia – a review of current management and future directions. Expert Opin Pharmacother. 2017;18(16):1739–1750. doi:10.1080/14656566.2017.1392508.
  • Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, et al. The polyanalgesic consensus conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation J Int Neuromodulation Soc. 2017;20(2):96–132.
  • Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010; 11(12):1827–1833. doi:10.1111/j.1526-4637.2010.01003.x.
  • Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–864. doi:10.1097/AJP.0b013e31827a72d2.
  • Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Südhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160–163.
  • Jo D, Jv H, Jd B, Rs W, Pm A, Al B, et al. Botulinum neurotoxin and dendrotoxin as probes for studies on transmitter release. J Physiol (Paris). 1984;79(4):280–303.
  • Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1–2):125–133. doi:10.1016/j.pain.2003.10.008.
  • Barbarisi M, Pace MC, Passavanti MB, Maisto M, Mazzariello L, Pota V, Aurilio C. Pregabalin and transcutaneous electrical nerve stimulation for postherpetic neuralgia treatment. Clin J Pain. 2010;26(7):567–572.
  • Xû G, Xú G, Feng Y, Tang WZ, Lv ZW. Transcutaneous electrical nerve stimulation in combination with cobalamin injection for postherpetic neuralgia: a single-center randomized controlled trial. Am J Phys Med Rehabil. 2014;93(4):287–298.
  • Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–979.
  • Woolf CJ, Mitchell D, Barrett GD. Antinociceptive effect of peripheral segmental electrical stimulation in the rat. Pain. 1980;8(2):237–252. doi:10.1016/0304-3959(88)90011-5.
  • Kalra A, Urban MO, Sluka KA. Blockade of opioid receptors in rostral ventral medulla prevents antihyperalgesia produced by transcutaneous electrical nerve stimulation (TENS). J Pharmacol Exp Ther. 2001;298(1):257–263.
  • Sluka KA, Deacon M, Stibal A, Strissel S, Terpstra A. Spinal blockade of opioid receptors prevents the analgesia produced by TENS in arthritic rats. J Pharmacol Exp Ther. 1999;289(2):840–846.
  • Stepanović A, Kolšek M, Kersnik J, Erčulj V. Prevention of post-herpetic neuralgia using transcutaneous electrical nerve stimulation. Wien Klin Wochenschr. 2015;127(9–10):369–374.
  • Amjad M, Mashhood AA. The efficacy of local infiltration of triamcinolone acetonide with lignocaine compared with lignocaine alone in the treatment of postherpetic neuralgia. J Coll Physicians Surg Pak. 2005;15(11):683–685.
  • Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001;87(1):3–11. doi:10.1093/bja/87.1.3.
  • Makharita MY, Amr YM, El-Bayoumy Y. Effect of early stellate ganglion blockade for facial pain from acute herpes zoster and incidence of postherpetic neuralgia. Pain Physician. 2012;15(6):467–474.
  • Jänig W, Levine JD, Michaelis M. Chapter 10. Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. In Kumazawa T, Kruger L, Mizumura K, editors. Progress in Brain Research [Internet]. Elsevier; 1996. p. 161–184. Available from: https://www.sciencedirect.com/science/article/pii/S0079612308610870.
  • Lin CS, Lin YC, Lao HC, Chen CC. Interventional treatments for postherpetic neuralgia: a systematic review. Pain Physician. 2019;22(3):209–228.
  • Ke M, Yinghui F, Yi J, Xeuhua H, Xiaoming L, Zhijun C, Chao H, Yingwei W. Efficacy of pulsed radiofrequency in the treatment of thoracic postherpetic neuralgia from the angulus costae: a randomized, double-blinded, controlled trial. Pain Physician. 2013;16(1):15–25.
  • Pi ZB, Lin H, He GD, Cai Z, Xu XZ. Randomized and controlled prospective trials of ultrasound-guided spinal nerve posterior ramus pulsed radiofrequency treatment for lower back post-herpetic neuralgia. Clin Ter. 2015;166(5):e301–e305. doi:10.7417/T.2015.1882.
  • Saxena AK, Lakshman K, Sharma T, Gupta N, Banerjee BD, Singal A. Modulation of serum BDNF levels in postherpetic neuralgia following pulsed radiofrequency of intercostal nerve and pregabalin. Pain Manag. 2016;6(3):217–227. doi:10.2217/pmt.16.3.
  • Wang D, Zhang K, Han S, Yu L. PainVision® apparatus for assessment of efficacy of pulsed radiofrequency combined with pharmacological therapy in the treatment of postherpetic neuralgia and correlations with measurements. BioMed Res Int [Internet]. 2017;2017:5670219. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357555/.
  • Iseki M, Morita Y, Nakamura Y, Ifuku M, Komatsu S. Efficacy of limited-duration spinal cord stimulation for subacute postherpetic neuralgia. Ann Acad Med Singap. 2009;38(11):1004–6.
  • Harke H, Gretenkort P, Ulrich Ladleif H, Koester P, Rahman S. Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain. Anesth Analg. 2002;94(3):694–700.
  • Prager JP. What does the mechanism of spinal cord stimulation tell us about complex regional pain syndrome? Pain Med. 2010;11(8):1278–1283. doi:10.1111/j.1526-4637.2010.00915.x.
  • Makharita MY, Amr YM, El‐Bayoumy Y. Single paravertebral injection for acute thoracic herpes zoster: a randomized controlled trial. Pain Pract. 2015;15(3):229–235. doi:10.1111/papr.12179.
  • Ji G, Niu J, Shi Y, Hou L, Lu Y, Xiong L. The effectiveness of repetitive paravertebral injections with local anesthetics and steroids for the prevention of postherpetic neuralgia in patients with acute herpes zoster. Anesth Analg. 2009;109(5):1651–1655. doi:10.1213/ANE.0b013e3181b79075.
  • Liu F, Lu GJ, Bai ZY. Efficacy of repetitive paravertebral block combined with medication in the treatment of zoster-related pain with different courses. Neurosciences (Riyadh). 2021;26(2):192–198. doi:10.17712/nsj.2021.2.20200124.
  • Aydın T, Balaban O, Ahiskalioglu A, Alici HA, Acar A. Ultrasound-guided erector spinae plane block for the management of herpes zoster pain: observational study. Cureus [Internet]. 2019;11(10):e5891. Available from: https://www.cureus.com/articles/23697-ultrasound-guided-erector-spinae-plane-block-for-the-management-of-herpes-zoster-pain-observational-study.
  • Deer TR, Pope JE, Lamer TJ, Grider JS, Provenzano D, Lubenow TR, FitzGerald JJ, Hunter C, Falowski S, Sayed D, et al. The neuromodulation appropriateness consensus committee on best practices for dorsal root ganglion stimulation. Neuromodulation. 2019;22(1):1–35.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.